The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Astellas Pharma
Stock and Other Ownership Interests - CVS; Merck; Seagen
Opioid use in locally advanced or metastatic urothelial carcinoma patients and matched non-cancer controls.
 
Simrun Kaur Grewal
Employment - Seagen
Stock and Other Ownership Interests - Seagen
Consulting or Advisory Role - Veritech Corporation
 
Zsolt Hepp
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Yutong Liu
Employment - Genesis Research
 
Rupali Fuldeore
Employment - Abbvie (I); Astellas Pharma
Stock and Other Ownership Interests - Abbvie (I)
 
Steve Sesterhenn
No Relationships to Disclose
 
Nancy N. Chang
Employment - Seagen
Stock and Other Ownership Interests - Seagen
 
Matt D. Galsky
Stock and Other Ownership Interests - Rappta Therapeutics
Consulting or Advisory Role - Aileron Therapeutics; Astellas Pharma; AstraZeneca; Basilea; BioMotiv; Bristol-Myers Squibb; Dendreon; Dracen; Dragonfly Therapeutics; EMD Serono; Genentech; GlaxoSmithKline; Incyte; Inovio Pharmaceuticals; Janssen; Lilly; Merck; Novartis; NuMab; Pfizer; Seagen; Urogen pharma
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Genentech/Roche (Inst); Janssen Oncology (Inst); Merck (Inst); Novartis (Inst)
Patents, Royalties, Other Intellectual Property - METHODS AND COMPOSITIONS FOR TREATING CANCER AND RELATED METHODS. MOUNT SINAI SCHOOL OF MEDICINE July 2012 Application number: 20120322792